Widely read:
Adobe Stock
Cipla' s Q4 FY25 results are in—and while the bottom line is beaming, the revenue growth engine is starting to hum rather than roar.
For Q4 FY25, Cipla posted a 30 per cent year-on-year jump in net profit to Rs 1,222 crore. That's impressive. But revenue rose just 9 per cent to Rs 6,730 crore—a decent figure, though it shows signs of slowing momentum.
What helped? Tighter cost control, a stronger product mix, and expanding margins. What didn't? Tepid growth in its key markets, especially the US and India, which together make up nearly 70 per cent of its sales.
What Cipla does
Cipla is a pharma heavyweight with a legacy stretching back to 1935. Known for its affordable generics, the company plays big in India, the US, and Africa. Its key focus areas include respiratory, cardiac, and urology therapies. Cipla makes money through prescription drugs, consumer health products, and bulk drug manufacturing (APIs).
Below are its key metrics:
| Metric | Value |
|---|---|
| Market cap | Rs 1,21,881 cr |
| P/E ratio | 24.43 |
| P/B ratio | 4.07 |
| Industry P/E | 34.05 |
| Debt-to-equity | 0.01 |
| ROE (Return on equity) | 16.63 per cent |
| ROCE (Return on capital employed) | 22.77 per cent |
| Dividend yield | 0.86 per cent |
| Book value | Rs 370.78 |
| EPS (Earnings per share) | Rs 61.79 |
Cipla Q4 FY25 snapshot
| Metric | Q4 FY25 | Change (YoY) |
|---|---|---|
| Revenue | Rs 6,730 cr | +9.2 per cent |
| EBITDA | Rs 1,538 cr | +16.8 per cent |
| Net profit | Rs 1,222 cr | +30.1 per cent |
| EBITDA margin | 22.8 per cent | +150 bps |
| PAT margin | 18.2 per cent | +292 bps |
| R&D spend | Rs 426 cr | 6.3 per cent of sales |
India (Rs 2,622 crore) and North America (Rs 1,967 crore approx.) remained the top revenue contributors. The India business benefited from chronic therapy launches like Foracort G and Empagliflozin. In the US, complex generic launches such as Nano Paclitaxel added some tailwind.
Here's why it matters
It's not every day a pharma company clocks a 30 per cent jump in profit while keeping costs in check and maintaining low debt. Cipla's cash pile is now over Rs 10,800 crore, giving it serious room to invest, acquire, or simply stay resilient in tough markets.
But the slowdown in revenue growth raises a red flag. The company has squeezed out gains from existing operations, but fresh growth may need big launches, global tie-ups, or smart acquisitions.
So, should investors bite?
Cipla is a solid, defensive pick in pharma. It's well-managed, debt-light, and consistently profitable. If you're in it for stability and steady compounding, it checks the right boxes. But if you're chasing rapid growth, this may not be the fastest horse in the race—yet.
Value Research Online stock rating:
-
Quality:
7/10
-
Growth:
7/10
-
Valuation:
5/10
-
Momentum:
7/10
Why smart investors trust expert research
Want sharper, stock-focused guidance beyond gold? Value Research Stock Advisor gives you expert-researched stock recommendations, long-term strategies and the discipline to help you build real wealth. Join thousands of successful Indian investors who trust us to guide their equity journey.
Check it out here: Value Research Stock Advisor
Disclaimer: This story was created with the assistance of artificial intelligence and is intended for informational purposes only. Please take it with a pinch of salt and do your own research or consult a financial advisor before making investment decisions.
Disclaimer: This content is for information only and should not be considered investment advice or a recommendation.
For grievances: [email protected]
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
